DEF 14A: Allogene Therapeutics Sets Date for 2024 Annual Stockholders Meeting

Allogene Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 5, 2024, to vote on director elections, executive compensation, and auditor ratification.

Summary

• Allogene Therapeutics will hold its 2024 Annual Meeting of Stockholders on June 5, 2024, at 8:00 a.m. Pacific Time, as a virtual meeting.
• Stockholders of record as of April 17, 2024, are eligible to vote.
• The meeting will address the election of four directors to hold office until the 2027 Annual Meeting, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The Board of Directors recommends voting 'For' the election of the director nominees and the ratification of the auditor.
• The company is committed to Environmental, Social, and Governance (ESG) practices, including diversity and inclusion, competitive pay and benefits, employee development, and environmental sustainability.
• The Board has adopted an incentive compensation recoupment policy (the Clawback Policy) in accordance with Rule 10D-1 of the Exchange Act and Nasdaq Rule 5608 that requires the Company to recover excess incentive compensation that was paid to an executive officer based in whole or in part on financial results that were subject to a restatement of the Company's financial statements.

Sentiment

Score: 7

Explanation: The document is primarily factual and informative, with a neutral to slightly positive tone. The company highlights its commitment to ESG and DEIB, which contributes to a positive sentiment. However, the restatement of financial statements and a few late filings temper the overall sentiment.

Positives

• The company is committed to sustainable business operations, thoughtful social responsibility initiatives, and maintaining governance structures that promote effective oversight.
• The company fosters an inclusive environment through respect, collaboration, and open communication.
• The company believes in equal pay for equal work and regularly reviews compensation practices.
• The company is committed to sustainable business practices that minimize employee and environmental risks.
• The company has a clawback policy in place to recover excess incentive compensation paid to executive officers based on financial results that were subject to a restatement.

Negatives

• The company restated previously issued financial statements for the years ended December 31, 2020, 2021 and 2022 and interim quarters during 2022 and 2023 due to non-cash accounting adjustments associated with the formation of the Allogene Overland Biopharm joint venture in December 2020.
• A Form 4 filed on behalf of Earl Douglas was filed late due to a delay in obtaining an updated EDGAR passphrase, and a Form 4 filed on behalf of Lillian Smith, our former Interim General Counsel and Compliance Officer, was filed late due to an administrative oversight.

Risks

• The company operates in a very technical, highly regulated, and extremely competitive industry where its long-term success is highly dependent on the specialized skills, talent, and dedication of its executive officers.
• The company's forward-looking statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements.
• The company's limitation of liability and indemnification provisions in its Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties.

Future Outlook

The company's forward-looking statements include statements regarding the company's commitment to progress ESG matters, plans and expectations regarding executive compensation, development plans and business strategy, the potential of the company's product candidates, ongoing and planned clinical trials, and the potential market opportunity of the company's product candidates and competitive landscape.

Management Comments

• The Nominating and Corporate Governance Committee seeks to assemble a Board of Directors that, as a whole, possesses the appropriate balance of professional and industry knowledge, financial expertise and high-level management experience necessary to oversee and direct the Company’s business.
• We are strongly committed to progress on ESG matters.
• We are committed to cultivating, fostering, and preserving a culture of diversity, equity, inclusion and belonging (DEIB).

Industry Context

Allogene Therapeutics is operating in the competitive field of biotechnology, specifically focused on allogeneic CAR T-cell therapies. The company's strategic decisions, such as prioritizing the ALPHA3 trial, reflect the dynamic nature of the industry and the need to adapt to emerging clinical data and market opportunities.

Comparison to Industry Standards

• The document references several peer companies used for executive compensation benchmarking, including Agios Pharmaceuticals, Beam Therapeutics, CRISPR Therapeutics, and others.
• These companies are generally in the biotechnology or biopharmaceutical space, with a focus on innovative therapies and similar market capitalizations.
• The document also mentions specific CAR T-cell therapies like Kymriah, indicating Allogene's position within the immuno-oncology landscape.

Related Party Transactions

• The company has entered into consulting agreements with Two River, LLC and Bellco Capital LLC, which are affiliated with directors and executive officers.
• The company has a sublease agreement with Bellco for office space in Los Angeles.

Stakeholder Impact

• Shareholders are asked to vote on key proposals that will shape the company's direction.
• Employees are impacted by the company's commitment to DEIB and competitive compensation and benefits.
• The company's ESG initiatives aim to minimize environmental impact and promote social responsibility.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will announce preliminary voting results at the Annual Meeting and publish final results in a Form 8-K.

Key Dates

Keywords

stockholders meeting, proxy statement, executive compensation, board of directors, audit committee, ESG, directors, Allogene Therapeutics, governance